Key result
High admission PENK levels linked to increased mortality and rehospitalization in HF patients.
Why the study?
The prognostic value of proenkephalin levels at admission in patients with heart failure for outcomes such as mortality, rehospitalization, and renal function decline was unclear.
Do high proenkephalin (PENK) levels at admission predict worsened prognosis in patients with heart failure?
Meta-Analysis
Do high proenkephalin (PENK) levels at admission predict worsened prognosis in patients with heart failure?
High proenkephalin levels at admission may serve as a prognostic biomarker for worsened outcomes in heart failure patients.
May support PENK for HF risk stratification; extends meta-analytic evidence on neurohormonal prognostic markers.
Over the last several years, the use of biomarkers in the diagnosis of patients with heart failure (HF) has skyrocketed. Natriuretic peptides are currently the most widely used biomarker in the diagnosis and prognosis of individuals with HF. Proenkephalin (PENK) activates delta-opioid receptors in cardiac tissue, resulting in a decreased myocardial contractility and heart rate. However, the goal of this meta-analysis is to evaluate the association between the PENK level at the time of admission and prognosis in patients with HF, such as all-cause mortality, rehospitalization, and decreasing renal function. High PENK levels have been associated with a worsened prognosis in patients with HF.
No takes yet. Share an insight, caveat, or question.
Siranart et al. (2023) conducted a meta-analysis in Heart Failure. Proenkephalin (PENK) level at admission was evaluated on Prognosis (all-cause mortality, rehospitalization, and decreasing renal function). High proenkephalin (PENK) levels at admission were associated with a worsened prognosis, including all-cause mortality and rehospitalization, in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: